Syndromic Multiplex Diagnostic Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 2.68 Billion |
| Market Size (2029) | USD 3.89 Billion |
| CAGR (2024 - 2029) | 7.66 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Syndromic Multiplex Diagnostic Market Analysis
The Syndromic Multiplex Diagnostic Market size is estimated at USD 2.68 billion in 2024, and is expected to reach USD 3.89 billion by 2029, growing at a CAGR of 7.66% during the forecast period (2024-2029).
Due to the high number of COVID-19 cases in the early stages of the pandemic, hospitals worldwide canceled medical visits, and the target population remained indoors fearing infection. Research and development efforts increased for advanced Molecular Diagnostic solutions for the detection of SARS-CoV-2, thereby contributing to the growth of the Molecular Diagnostic Market. Major players focused on innovations and increased investments in developing devices or panels for multiplexed detection of the virus, thus enhancing the Multiplexed Diagnostics Market. For instance, in May 2022, Cipla commercially launched the RT-Direct multiplex COVID-19 RT-PCR test kit in India through a partnership with Genese2Me Pvt Ltd, contributing to the growth of the Multiplex PCR Kit Market. Therefore, the pandemic is expected to contribute to the growth of the Diagnostic Market. However, the emergence of various mutant strains of COVID-19 is expected to contribute to the demand for advanced Point of Care Molecular Diagnostics, thereby resulting in the growth of the market during the post-pandemic period.
The market is driven by factors such as the growing burden of diseases in recent years. This created a higher demand for accurate and Rapid Diagnostic Testing, thereby contributing to the growth of the market over the forecast period. For instance, as stated by data from the World Health Organization 2021, chronic respiratory diseases affect more than one billion people globally. Additionally, as per data from Lung India as of August 2022, the prevalence of asthma among Indian children was around 18.2%. The same source suggests that there is a high prevalence of severe asthma in the emerging markets of the Middle East and Africa as well as Latin America, compared to the mid-range prevalence in North America and Europe. Given this high prevalence of respiratory diseases, there is a growing demand for efficient Respiratory Pathogen Testing solutions. To detect such rare diseases, several Molecular Testing Panels have been developed. For instance, an Elsevier article published in April 2021 stated that researchers developed a Multiplex PCR based diagnostic method, which showed rapid and accurate detection of Alzheimer's disease biomarkers. Such developments and research are increasing the demand for syndromic multiplex diagnostics, thereby driving the growth of the Multiplexed Diagnostics Market.
In addition, the Australian Federation of AIDS Organizations (AFAO) estimated that around 29,090 people are living with human immunodeficiency virus infection (HIV), and 2,610 people were unaware they were positive in 2020. Western blotting is the gold-standard test for the detection of HIV. However, the demand for Syndromic Testing is increasing with the rise in cases of various diseases. Thus, the growing burden of such diseases demands more accurate and rapid Infectious Disease Testing methods, and it is expected to propel the studied market growth over the forecast period.
Furthermore, the rising product launches are expected to contribute to the growth of the market over the forecast period. For instance, in October 2021, Hologic launched Novodiag System in Europe. Novodiag is a fully automated Molecular Diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. Additionally, in June 2021, Eurofins launched a Multiplex PCR assay for rapid detection of the B.1.617 SARS-CoV-2 variant. Such developments are anticipated to fuel the growth of the Multiplexed Diagnostics Market.
Therefore, owing to the above-mentioned factors, the Diagnostic Market is expected to grow over the forecast period. However, the lack of skilled professionals and the inability in detecting asymptomatic cases are factors that are anticipated to hinder market growth.
Syndromic Multiplex Diagnostic Market Trends
This section covers the major market trends shaping the Syndromic Multiplex Diagnostic Market according to our research experts:
Gastrointestinal Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period
The advantages of syndromic panels for gastrointestinal (GI) illnesses are similar to respiratory syndromic panels. They quickly identify a wide spectrum of GI pathogens with great sensitivity and specificity, enhancing Pathogen Detection. As there is a lot of clinical overlap between pathogens that cause GI disease, GI Syndromic Testing panels are very useful.
Additionally, overall, syndromic testing in GI promises comprehensive testing as well as considerably reduced turnaround times, enhanced sensitivity, increased pathogen identification, and streamlined ordering techniques, all of which are aimed at improving clinical outcomes. The shortened workflow that results has a significant impact on lab efficiency. For instance, data updated by BioFire Diagnostics in 2022 shows that the BioFire FilmArray GI Panel is a quick Multiplex PCR test that identifies the 22 most common pathogens associated with gastroenteritis from a single patient sample, including 13 bacteria, 5 viruses, and 4 parasites, with findings available in about 1 hour. Such advantages of technologically advanced panels developed for GI diseases are anticipated to drive segment growth.
Moreover, recent developments and advancements in the segment are increasing. For instance, in January 2022, Qiagen expanded the menu of its QIAstat-Dx Syndromic Testing system and expects to release QIAstat-Dx Rise, a higher throughput version of the device, later in 2022. The ability to distinguish between gastrointestinal pathogens as well as meningitis and encephalitis illnesses has been added to the new QIAstat-Dx menu. Such advancements are expected to fuel the growth of the Multiplexed Diagnostics Market.
Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the forecast period.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period
North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the North America Multiplexed Diagnostics Market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of various communicable or non-communicable diseases. Additionally, the rising geriatric population across the United States is the primary driver for the United States Syndromic Multiplex Diagnostic Market.
For instance, the HIV Government factsheet last updated in June 2021 shows that in the United States, approximately 1.2 million people are infected with human immunodeficiency virus (HIV), and about a third of the target population were unaware that they have HIV and require testing. Thus, the prevalence of infectious diseases in the United States demands Syndromic Multiplex Diagnostic testing and is expected to drive market growth over the forecast period.
Moreover, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For example, in January 2022, QIAGEN reported significant enhancements in the commercialization of its QIAstat-Dx Syndromic Testing solution, which enables laboratories and hospitals to test patients for multiple pathogens from one sample. The test enhancements for QIAstat-Dx involved in the application for the United States regulatory approval of a Gastrointestinal (GI) panel that can detect 22 common viral, bacterial, and parasite pathogens that can cause potentially fatal diseases.
In addition, in December 2021, Applied BioCode received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) for its BioCode CoV-2 Flu Plus Assay. This PCR-based, Multiplex Molecular Diagnostic assay can simultaneously detect and differentiate between SARS-CoV-2, Influenza A with subtypes (seasonal H1, 2009 H1N1, H3, Influenza B), and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens.
Therefore, owing to the factors mentioned above, North America is predicted to be the major market for Syndromic Multiplex Diagnostics, which is expected to witness growth over the forecast period.
Syndromic Multiplex Diagnostic Industry Overview
The Syndromic Multiplex Diagnostic Market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are BIOMERIEUX, DiaSorin S.p.A (Luminex Corporation), QIAGEN, Applied BioCode, and Akonni Biosystems.
Syndromic Multiplex Diagnostic Market Leaders
-
Akonni Biosystems
-
Applied BioCode
-
QIAGEN
-
BIOMERIEUX SA
-
DiaSorin S.p.A (Luminex Corporation)
*Disclaimer: Major Players sorted in no particular order
Syndromic Multiplex Diagnostic Market News
- In March 2022, Applied BioCode signed an agreement with Hardy Diagnostics for the distribution of the MDx-3000 System and its comprehensive menu for the diagnosis of upper respiratory infections, and gastrointestinal infections as well as a suite of Analyte Specific Reagents (ASRs). Under this agreement, Hardy Diagnostics is responsible to distribute the Automated High Throughput Multiplex Molecular Diagnostic System (MDx-3000) in the United States.
- In January 2022, Seegene Inc. South Korean molecular diagnostic company received approval for its Allplex SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order. The Allplex SARS CoV-2 FluA/FluB/RSV Assay from Seegene is a multiplex real-time PCR assay that allows for both amplification and differentiation of respiratory symptoms. It can distinguish between Influenza A, B, RSV, and COVID-19 in a single test.
Syndromic Multiplex Diagnostic Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Accurate and Rapid Results
4.2.2 Quick Access to the Treatment
4.3 Market Restraints
4.3.1 Lack of Skilled Professional
4.3.2 Inability in Detecting Asymptomatic Cases
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type of Syndrome
5.1.1 Respiratory
5.1.2 Gastrointestinal
5.1.3 Central Nervous System
5.1.4 Other Types of Syndromes (cUTI and STDs)
5.2 By End-User
5.2.1 Hospitals
5.2.2 Diagnostics Laboratories
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 bioMerieux
6.1.2 Qiagen
6.1.3 DiaSorin S.p.A (Luminex Corporation)
6.1.4 Applied BioCode
6.1.5 Akonni Biosystems
6.1.6 Thermo Fisher Scientific, inc.
6.1.7 Abbott Laboratories
6.1.8 Accelerate Diagnostic
6.1.9 Becton, Dickinson and Company
6.1.10 Hologic, Inc.
6.1.11 F. Hoffmann-La Roche Ltd
6.1.12 Abacus Diagnostica Oy
6.1.13 Accelerate Diagnostics, Inc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Syndromic Multiplex Diagnostic Industry Segmentation
As per the scope of this report, a syndromic multiplex diagnostic test employs testing of various pathogens in a single test reaction and helps healthcare providers to deliver efficient medications in proper time by minimizing uncertainty and mistakes that occur while testing for infection. The syndromic multiplex diagnostic test gives more accurate, realistic, and comprehensive results in critical care. The Syndromic Multiplex Diagnostic Market is segmented by Type of Syndrome (Respiratory, Gastrointestinal, Central Nervous System and Other Types of Syndromes (cUTI and STDs)), By End-User (Hospitals, Diagnostics Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Type of Syndrome | |
| Respiratory | |
| Gastrointestinal | |
| Central Nervous System | |
| Other Types of Syndromes (cUTI and STDs) |
| By End-User | |
| Hospitals | |
| Diagnostics Laboratories | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Syndromic Multiplex Diagnostic Market Research FAQs
How big is the Syndromic Multiplex Diagnostic Market?
The Syndromic Multiplex Diagnostic Market size is expected to reach USD 2.68 billion in 2024 and grow at a CAGR of 7.66% to reach USD 3.89 billion by 2029.
What is the current Syndromic Multiplex Diagnostic Market size?
In 2024, the Syndromic Multiplex Diagnostic Market size is expected to reach USD 2.68 billion.
Who are the key players in Syndromic Multiplex Diagnostic Market?
Akonni Biosystems, Applied BioCode, QIAGEN, BIOMERIEUX SA and DiaSorin S.p.A (Luminex Corporation) are the major companies operating in the Syndromic Multiplex Diagnostic Market.
Which is the fastest growing region in Syndromic Multiplex Diagnostic Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Syndromic Multiplex Diagnostic Market?
In 2024, the North America accounts for the largest market share in Syndromic Multiplex Diagnostic Market.
What years does this Syndromic Multiplex Diagnostic Market cover, and what was the market size in 2023?
In 2023, the Syndromic Multiplex Diagnostic Market size was estimated at USD 2.49 billion. The report covers the Syndromic Multiplex Diagnostic Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Syndromic Multiplex Diagnostic Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Syndromic Multiplex Diagnostic Industry Report
The Global Syndromic Multiplex Diagnostic Market is segmented by type of syndrome, including respiratory, gastrointestinal, central nervous system, and other types of syndromes such as cUTI and STDs. The market is also segmented by end-users, which include hospitals, diagnostics laboratories, and other end users. The report provides a comprehensive market overview, offering insights into market growth and the industry outlook across various geographic regions, including North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
The industry report highlights the market trends and market segmentation, providing valuable market data and industry statistics. The market forecast and market predictions indicate the expected market value and market size, offering a detailed industry analysis and market review. The report also includes industry research and industry reports, which are essential for understanding the market dynamics and market leaders.
The report example and report PDF download offer a sample of the industry analysis, allowing for an in-depth understanding of the market growth rate and industry sales. The market analysis and market research provide a historical overview and a forecast outlook, ensuring that the industry information is comprehensive and up-to-date. The market outlook and market segmentation are crucial for identifying key growth areas and market leaders.
Overall, the report provides a thorough examination of the syndromic multiplex diagnostic market, including market trends, market growth, and industry trends. The market forecast and market overview offer a clear picture of the market's future, supported by detailed industry research and market data. The industry reports and market predictions ensure that stakeholders have access to accurate and reliable information, aiding in strategic decision-making and market planning.
Syndromic Multiplex Diagnostic Market Report Snapshots
